advertisement
Shah M 30
Showing records 1 to 25 | Display all abstracts from Shah M109487 Necrotizing Scleritis: A Review
Dutta Majumder P
Ocular Immunology and Inflammation 2023; 0: 1-15
111960 Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma
Karg MM
Cellular reprogramming 2023; 25: 288-299
109727 Managing primary open-angle glaucoma in the setting of suboptimal surgical outcomes in the fellow eye
Huang MJ; Samuelson TW
Journal of Cataract and Refractive Surgery 2023; 49: 764
111960 Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma
Lu YR
Cellular reprogramming 2023; 25: 288-299
109487 Necrotizing Scleritis: A Review
Agarwal S
Ocular Immunology and Inflammation 2023; 0: 1-15
111960 Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma
Refaian N
Cellular reprogramming 2023; 25: 288-299
109487 Necrotizing Scleritis: A Review
Shah M
Ocular Immunology and Inflammation 2023; 0: 1-15
109727 Managing primary open-angle glaucoma in the setting of suboptimal surgical outcomes in the fellow eye
De Francesco T; Levin A
Journal of Cataract and Refractive Surgery 2023; 49: 764
109487 Necrotizing Scleritis: A Review
Srinivasan B
Ocular Immunology and Inflammation 2023; 0: 1-15
111960 Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma
Cameron J
Cellular reprogramming 2023; 25: 288-299
109727 Managing primary open-angle glaucoma in the setting of suboptimal surgical outcomes in the fellow eye
Sieck E
Journal of Cataract and Refractive Surgery 2023; 49: 764
111960 Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma
Hoffmann E
Cellular reprogramming 2023; 25: 288-299
109487 Necrotizing Scleritis: A Review
K P; Iyer G
Ocular Immunology and Inflammation 2023; 0: 1-15
109727 Managing primary open-angle glaucoma in the setting of suboptimal surgical outcomes in the fellow eye
Gazzard G
Journal of Cataract and Refractive Surgery 2023; 49: 764
111960 Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma
Hoppe C
Cellular reprogramming 2023; 25: 288-299
109727 Managing primary open-angle glaucoma in the setting of suboptimal surgical outcomes in the fellow eye
Porter M
Journal of Cataract and Refractive Surgery 2023; 49: 764
111960 Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma
Shirahama S
Cellular reprogramming 2023; 25: 288-299
109487 Necrotizing Scleritis: A Review
Sharma N; Biswas J
Ocular Immunology and Inflammation 2023; 0: 1-15
111960 Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma
Shah M
Cellular reprogramming 2023; 25: 288-299
109727 Managing primary open-angle glaucoma in the setting of suboptimal surgical outcomes in the fellow eye
Gallardo M
Journal of Cataract and Refractive Surgery 2023; 49: 764
111960 Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma
Krasniqi D
Cellular reprogramming 2023; 25: 288-299
109487 Necrotizing Scleritis: A Review
McCluskey P
Ocular Immunology and Inflammation 2023; 0: 1-15
109727 Managing primary open-angle glaucoma in the setting of suboptimal surgical outcomes in the fellow eye
Chang RT
Journal of Cataract and Refractive Surgery 2023; 49: 764
111960 Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma
Krishnan A
Cellular reprogramming 2023; 25: 288-299
109727 Managing primary open-angle glaucoma in the setting of suboptimal surgical outcomes in the fellow eye
Liu WW; Chaya C
Journal of Cataract and Refractive Surgery 2023; 49: 764
